Understand · Treat · Recover
Multiple Myeloma
Myeloma is a cancer of plasma cells. Treatment aims to control the disease, protect organs and preserve daily function.
For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.
Chapter 11 of 20 · D · Multiple myeloma
Plasma cells and monoclonal proteins
Healthy plasma cells make antibodies. A myeloma clone may produce one abnormal antibody, called a monoclonal or M protein, or only parts called light chains. Tests include serum protein electrophoresis, immunofixation and serum free light chains; urine studies may also be needed. Some myelomas produce little measurable protein. A monoclonal protein alone does not prove active myeloma. Kidney impairment can affect light-chain measurements, so interpretation needs context.
MGUS and smoldering myeloma
Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condition with a smaller abnormal plasma-cell burden and no myeloma-defining damage. Smoldering myeloma has a higher burden but lacks myeloma-defining events. Both require risk-based assessment and monitoring; neither should automatically be labelled symptomatic cancer. Some high-risk smoldering cases may be considered for early treatment or a clinical trial under specialist guidance. Do not assume every person with smoldering disease should receive full myeloma treatment.
When myeloma becomes treatment-requiring
CRAB summarizes high calcium, renal (kidney) impairment, anemia and destructive bone lesions attributable to the plasma-cell disorder. Modern criteria also include certain biomarkers that predict a high risk of progression before organ damage develops. These include marrow clonal plasma cells of at least 60%; an involved-to-uninvolved free light-chain ratio of at least 100 with involved light chain at least 100 mg/L; or more than one MRI focal lesion at least 5 mm. These results must be assessed with the full diagnostic criteria, not used as a self-diagnosis checklist.
Marrow, FISH and imaging
Marrow sampling assesses plasma cells and allows genetic risk testing, often with plasma-cell-enriched FISH. A negative panel with too few cells can have limited sensitivity. Whole-body low-dose CT, PET-CT or MRI is selected according to the clinical question and availability. A routine isotope bone scan is not the preferred test to exclude myeloma bone disease. Risk assessment combines disease stage, genetic findings, organ function and response.
Modern combination treatment
Initial treatment often combines medicines from different classes: a proteasome inhibitor such as bortezomib, an immunomodulatory medicine such as lenalidomide, a steroid and, in suitable settings, an anti-CD38 antibody such as daratumumab. Combinations and doses are adapted to fitness, kidney function, neuropathy and access. Clot prevention, antiviral prevention and bone-protective treatment may be needed. These are prescribed individually; do not start aspirin, supplements or painkillers without checking safety.
Autologous transplant and maintenance
Autologous transplantation uses the person’s own stem cells after high-dose treatment. It can deepen and prolong remission but is not normally described as a cure for myeloma. Eligibility is based on fitness and organ function, not age alone. Maintenance medicine helps sustain control; choice depends on disease risk, previous treatment and tolerance. Non-transplant treatment is an active approach, not abandonment of care.
Relapse, kidneys and bones
Myeloma commonly relapses, and subsequent treatment depends on which medicines have stopped working. New combinations, CAR-T or bispecific antibodies are options in selected settings. Persistent infections and low antibody levels require attention. Seek urgent care for reduced urine, confusion, severe dehydration or new back pain with weakness or bladder/bowel changes. Discuss pain control, dental assessment before bone-strengthening medicines and safe activity. Many people experience meaningful remissions, but duration varies widely.
Take-home message
Protecting kidneys and bones is part of treating myeloma, not an optional extra.
Common questions
Is MGUS the same as cancer?
No. It is a precursor condition that usually needs monitoring rather than cancer treatment.
Does dialysis mean treatment cannot help?
No. Myeloma can be treated in people on dialysis. Kidney recovery is variable and depends on the cause, severity and speed of disease control.
Sources and further reading
Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.